Basel, July 13, 2001
Roche Diagnostic introduces significant new instrument in the clinical laboratory - the E170 module for MODULAR ANALYTICS
Roche Diagnostics today announced the launch of the E170 module for MODULAR ANALYTICS. The E170 module is a high volume throughput heterogeneous immunochemistry analyser, offering 50 different ECL (Electrochemiluminescence) based assays for testing in the areas of cardiology, fertility, thyroid function, oncology, anaemia, infectious disease, and osteoporosis. With the launch of this module, Roche Diagnostics takes the next step towards the integrated, consolidated Serum Work Area (SWA) platform comprising clinical chemistry and immunodiagnostics.
The MODULAR ANALYTICS E module combinations excel through customer benefits such as user-friendliness, customisability, flexibility and security. MODULAR ANALYTICS E combinations can be enhanced on-site incurring minimal disruption of workflow, with all configurations being tailored to meet the laboratories' individual needs. Combining four E170 modules provides laboratories with up to a maximum of 680 heterogeneous immunochemistry test results per hour, up to 100 reagent slots on board and six hours of walk-away time.
The E170 module is planned to be combined with the existing clinical chemistry modules such as D2400, P800 and ISE 900/1800 in a consolidated SWA configuration. Due to the common, single user interface, training for lab personnel for clinical chemistry testing, homogeneous and heterogeneous immunoassay testing can be standardised. Specimen handling and splitting requirements are also reduced significantly. The E170 module for MODULAR ANALYTICS is a part of the MODULAR SYSTEMS family, which has an established track record of reliability and operational efficiency with its 3 lane processing, bi-directional sample transport system and Intelligent Process Management (IPM).
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well being and quality of life. Roche has approximately 64,000 employees and sells its products in over 170 countries. In 2000 the Roche Group posted sales of 28,7 billion Swiss francs and an adjusted net income of 5,0 billion Swiss francs. Roche's Diagnostics Division supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide.